187 related articles for article (PubMed ID: 37756525)
21. Tyrosine kinase inhibitor-induced defects in DNA repair sensitize FLT3(ITD)-positive leukemia cells to PARP1 inhibitors.
Maifrede S; Nieborowska-Skorska M; Sullivan-Reed K; Dasgupta Y; Podszywalow-Bartnicka P; Le BV; Solecka M; Lian Z; Belyaeva EA; Nersesyan A; Machnicki MM; Toma M; Chatain N; Rydzanicz M; Zhao H; Jelinek J; Piwocka K; Sliwinski T; Stoklosa T; Ploski R; Fischer T; Sykes SM; Koschmieder S; Bullinger L; Valent P; Wasik MA; Huang J; Skorski T
Blood; 2018 Jul; 132(1):67-77. PubMed ID: 29784639
[TBL] [Abstract][Full Text] [Related]
22. GFI1 facilitates efficient DNA repair by regulating PRMT1 dependent methylation of MRE11 and 53BP1.
Vadnais C; Chen R; Fraszczak J; Yu Z; Boulais J; Pinder J; Frank D; Khandanpour C; Hébert J; Dellaire G; Côté JF; Richard S; Orthwein A; Drobetsky E; Möröy T
Nat Commun; 2018 Apr; 9(1):1418. PubMed ID: 29651020
[TBL] [Abstract][Full Text] [Related]
23. Superior efficacy of co-targeting GFI1/KDM1A and BRD4 against AML and post-MPN secondary AML cells.
Fiskus W; Mill CP; Nabet B; Perera D; Birdwell C; Manshouri T; Lara B; Kadia TM; DiNardo C; Takahashi K; Daver N; Bose P; Masarova L; Pemmaraju N; Kornblau S; Borthakur G; Montalban-Bravo G; Manero GG; Sharma S; Stubbs M; Su X; Green MR; Coarfa C; Verstovsek S; Khoury JD; Vakoc CR; Bhalla KN
Blood Cancer J; 2021 May; 11(5):98. PubMed ID: 34016956
[TBL] [Abstract][Full Text] [Related]
24. Enhancer Activation by Pharmacologic Displacement of LSD1 from GFI1 Induces Differentiation in Acute Myeloid Leukemia.
Maiques-Diaz A; Spencer GJ; Lynch JT; Ciceri F; Williams EL; Amaral FMR; Wiseman DH; Harris WJ; Li Y; Sahoo S; Hitchin JR; Mould DP; Fairweather EE; Waszkowycz B; Jordan AM; Smith DL; Somervaille TCP
Cell Rep; 2018 Mar; 22(13):3641-3659. PubMed ID: 29590629
[TBL] [Abstract][Full Text] [Related]
25. PTEN loss compromises homologous recombination repair in astrocytes: implications for glioblastoma therapy with temozolomide or poly(ADP-ribose) polymerase inhibitors.
McEllin B; Camacho CV; Mukherjee B; Hahm B; Tomimatsu N; Bachoo RM; Burma S
Cancer Res; 2010 Jul; 70(13):5457-64. PubMed ID: 20530668
[TBL] [Abstract][Full Text] [Related]
26. Poly(ADP-ribose) polymerase inhibitor ABT-888 potentiates the cytotoxic activity of temozolomide in leukemia cells: influence of mismatch repair status and O6-methylguanine-DNA methyltransferase activity.
Horton TM; Jenkins G; Pati D; Zhang L; Dolan ME; Ribes-Zamora A; Bertuch AA; Blaney SM; Delaney SL; Hegde M; Berg SL
Mol Cancer Ther; 2009 Aug; 8(8):2232-42. PubMed ID: 19671751
[TBL] [Abstract][Full Text] [Related]
27. Phase II study of targeted therapy with temozolomide in acute myeloid leukaemia and high-risk myelodysplastic syndrome patients pre-screened for low O(6) -methylguanine DNA methyltransferase expression.
Brandwein JM; Kassis J; Leber B; Hogge D; Howson-Jan K; Minden MD; Galarneau A; Pouliot JF
Br J Haematol; 2014 Dec; 167(5):664-70. PubMed ID: 25160658
[TBL] [Abstract][Full Text] [Related]
28. Co-inhibition of HDAC and MLL-menin interaction targets MLL-rearranged acute myeloid leukemia cells via disruption of DNA damage checkpoint and DNA repair.
Ye J; Zha J; Shi Y; Li Y; Yuan D; Chen Q; Lin F; Fang Z; Yu Y; Dai Y; Xu B
Clin Epigenetics; 2019 Oct; 11(1):137. PubMed ID: 31590682
[TBL] [Abstract][Full Text] [Related]
29. Temozolomide: mechanisms of action, repair and resistance.
Zhang J; Stevens MF; Bradshaw TD
Curr Mol Pharmacol; 2012 Jan; 5(1):102-14. PubMed ID: 22122467
[TBL] [Abstract][Full Text] [Related]
30. Pharmacological inhibition of poly(ADP-ribose) polymerase-1 modulates resistance of human glioblastoma stem cells to temozolomide.
Tentori L; Ricci-Vitiani L; Muzi A; Ciccarone F; Pelacchi F; Calabrese R; Runci D; Pallini R; Caiafa P; Graziani G
BMC Cancer; 2014 Mar; 14():151. PubMed ID: 24593254
[TBL] [Abstract][Full Text] [Related]
31. HMG20B stabilizes association of LSD1 with GFI1 on chromatin to confer transcription repression and leukemia cell differentiation block.
Maiques-Diaz A; Nicosia L; Basma NJ; Romero-Camarero I; Camera F; Spencer GJ; Amaral FMR; Simeoni F; Wingelhofer B; Williamson AJK; Pierce A; Whetton AD; Somervaille TCP
Oncogene; 2022 Oct; 41(44):4841-4854. PubMed ID: 36171271
[TBL] [Abstract][Full Text] [Related]
32. A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Myeloid Leukemia.
Gojo I; Beumer JH; Pratz KW; McDevitt MA; Baer MR; Blackford AL; Smith BD; Gore SD; Carraway HE; Showel MM; Levis MJ; Dezern AE; Gladstone DE; Ji JJ; Wang L; Kinders RJ; Pouquet M; Ali-Walbi I; Rudek MA; Poh W; Herman JG; Karnitz LM; Kaufmann SH; Chen A; Karp JE
Clin Cancer Res; 2017 Feb; 23(3):697-706. PubMed ID: 27503200
[TBL] [Abstract][Full Text] [Related]
33. The human GFI136N variant induces epigenetic changes at the Hoxa9 locus and accelerates K-RAS driven myeloproliferative disorder in mice.
Khandanpour C; Krongold J; Schütte J; Bouwman F; Vassen L; Gaudreau MC; Chen R; Calero-Nieto FJ; Diamanti E; Hannah R; Meyer SE; Grimes HL; van der Reijden BA; Jansen JH; Patel CV; Peeters JK; Löwenberg B; Dührsen U; Göttgens B; Möröy T
Blood; 2012 Nov; 120(19):4006-17. PubMed ID: 22932805
[TBL] [Abstract][Full Text] [Related]
34. Anti-leukemic Activity of AIU2008 in FLT3-ITD-positive Acute Myeloid Leukemia.
Kim HJ; Ryu H; Choi HK; Song JY; Hwang SG; Ahn J
Anticancer Res; 2021 Feb; 41(2):731-737. PubMed ID: 33517277
[TBL] [Abstract][Full Text] [Related]
35. XPO1 Inhibition using Selinexor Synergizes with Chemotherapy in Acute Myeloid Leukemia by Targeting DNA Repair and Restoring Topoisomerase IIα to the Nucleus.
Ranganathan P; Kashyap T; Yu X; Meng X; Lai TH; McNeil B; Bhatnagar B; Shacham S; Kauffman M; Dorrance AM; Blum W; Sampath D; Landesman Y; Garzon R
Clin Cancer Res; 2016 Dec; 22(24):6142-6152. PubMed ID: 27358488
[TBL] [Abstract][Full Text] [Related]
36. KDM6 demethylases integrate DNA repair gene regulation and loss of KDM6A sensitizes human acute myeloid leukemia to PARP and BCL2 inhibition.
Boila LD; Ghosh S; Bandyopadhyay SK; Jin L; Murison A; Zeng AGX; Shaikh W; Bhowmik S; Muddineni SSNA; Biswas M; Sinha S; Chatterjee SS; Mbong N; Gan OI; Bose A; Chakraborty S; Arruda A; Kennedy JA; Mitchell A; Lechman ER; Banerjee D; Milyavsky M; Minden MD; Dick JE; Sengupta A
Leukemia; 2023 Apr; 37(4):751-764. PubMed ID: 36720973
[TBL] [Abstract][Full Text] [Related]
37. A type I combi-targeting approach for the design of molecules with enhanced potency against BRCA1/2 mutant- and O6-methylguanine-DNA methyltransferase (mgmt)- expressing tumour cells.
Senhaji Mouhri Z; Goodfellow E; Jean-Claude B
BMC Cancer; 2017 Aug; 17(1):540. PubMed ID: 28800752
[TBL] [Abstract][Full Text] [Related]
38. Growth factor independent-1 maintains Notch1-dependent transcriptional programming of lymphoid precursors.
Phelan JD; Saba I; Zeng H; Kosan C; Messer MS; Olsson HA; Fraszczak J; Hildeman DA; Aronow BJ; Möröy T; Grimes HL
PLoS Genet; 2013; 9(9):e1003713. PubMed ID: 24068942
[TBL] [Abstract][Full Text] [Related]
39. NF-κB and Poly (ADP-ribose) Polymerase 1 Form a Positive Feedback Loop that Regulates DNA Repair in Acute Myeloid Leukemia Cells.
Li D; Luo Y; Chen X; Zhang L; Wang T; Zhuang Y; Fan Y; Xu J; Chen Y; Wu L
Mol Cancer Res; 2019 Mar; 17(3):761-772. PubMed ID: 30559256
[TBL] [Abstract][Full Text] [Related]
40. [Expression of growth-factor independence 1 in patients with leukemia and its significance].
Wang TT; Chen ZX; Cen JN; He J; Sheng HJ; Yao L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Aug; 18(4):834-7. PubMed ID: 20723283
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
